NEW YORK (Reuters Health) Jul 17 –
Findings from a small case study suggest that treatment with selective serotonin reuptake inhibitors (SSRI) during childhood can decrease growth.
As the use of such agents is expected to increase in pediatric populations, it is important that larger studies be conducted to verify this finding, the study authors note.
In the July issue of the Archives of Pediatric and Adolescent Medicine, Dr. Naomi Weintrob, from the Schneider Children’s Medical Center of Israel in Petah Tikva, and colleagues describe the medical histories of four children, 11 to 13 years of age.
Two of the children received SSRI therapy for obsessive-compulsive disorder and two were treated for Tourette syndrome.
The duration of therapy ranged from 6 months to 5 years.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!